^
    29d
    A Phase 2 Study to Evaluate DZD8586 in Adults With ITP (TAI-SHAN11) (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Dizal Pharmaceuticals
    New P2 trial
    |
    birelentinib (DZD8586)
    1m
    DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Dizal Pharmaceuticals | Recruiting --> Active, not recruiting | N=180 --> 59 | Trial completion date: Apr 2028 --> Aug 2026 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    birelentinib (DZD8586)
    2ms
    A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (clinicaltrials.gov)
    P3, N=250, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • Zydelig (idelalisib) • bendamustine • birelentinib (DZD8586)
    2ms
    A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) (clinicaltrials.gov)
    P2, N=66, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • birelentinib (DZD8586)
    5ms
    A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    New P2 trial
    |
    Venclexta (venetoclax) • birelentinib (DZD8586)
    5ms
    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • birelentinib (DZD8586)
    5ms
    A Phase 3 Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (clinicaltrials.gov)
    P3, N=250, Not yet recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    New P3 trial
    |
    Rituxan (rituximab) • Zydelig (idelalisib) • bendamustine • birelentinib (DZD8586)
    6ms
    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Dizal Pharmaceuticals
    New P1/2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • birelentinib (DZD8586)
    11ms
    A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) (clinicaltrials.gov)
    P1/2, N=17, Completed, Dizal Pharmaceuticals | Recruiting --> Completed | N=386 --> 17 | Trial completion date: Oct 2027 --> Feb 2024 | Trial primary completion date: Apr 2027 --> Feb 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    birelentinib (DZD8586)
    over1year
    DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) (clinicaltrials.gov)
    P2, N=180, Recruiting, Dizal Pharmaceuticals
    New P2 trial
    |
    birelentinib (DZD8586)
    over1year
    DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) (clinicaltrials.gov)
    P2, N=155, Recruiting, Dizal Pharmaceuticals
    New P2 trial
    |
    birelentinib (DZD8586)
    over1year
    TAI-SHAN5: DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=230, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting | N=20 --> 230
    Enrollment open • Enrollment change
    |
    birelentinib (DZD8586)